Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer

Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer

Introduction: Cyclin-dependent kinase (CDK)4/6 inhibitor is a first-line therapy for metastatic ER+/HER2-breast cancer. However, there are limited data on safety of combined radiotherapy (RT) and CDK4/6 inhibition. Methods: We conducted a retrospective study of women with metastatic breast cancer wh...

Full description

Bibliographic Details
Main Authors: Kristine N. Kim, Payal Shah, Amy Clark, Gary M. Freedman, Sana Dastgheyb, Andrew R. Barsky, Alexandra D. Dreyfuss, Neil K. Taunk
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Breast
Subjects:
CDK4/6 inhibitor
Radiotherapy
Palliation
Metastatic breast cancer
Safety
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977621004719

Internet

http://www.sciencedirect.com/science/article/pii/S0960977621004719

Similar Items